Brief: Guerbet: Positive Results For Phase III Clinical Trials Of Gadopiclenol

Guerbet SA

24/03/2021 08:12

March 24 (Reuters) - Guerbet SA  GRBT.PA :
    * GADOPICLENOL - POSITIVE RESULTS FOR PHASE III CLINICAL
TRIALS
    * GUERBET IS PLANNING TO MAKE REGULATORY SUBMISSIONS FROM
EARLY
2022 IN A WIDE RANGE OF INDICATIONS IN ADULTS AND CHILDREN FROM
2 YEARS OF AGE
    * ITS DIAGNOSTIC EFFICACY AND SAFETY HAVE BEEN EVALUATED IN
TWO
PHASE III CLINICAL STUDIES WITH A DOSE OF GADOLINIUM REDUCED BY
HALF COMPARED TO PRODUCTS ALREADY AVAILABLE ON MARKET
    * TOTAL OF 560 PATIENTS WERE RECRUITED FOR THESE TWO STUDIES
IN
OVER 60 HOSPITAL MEDICAL IMAGING DEPARTMENTS IN 13 COUNTRIES.
    * NO MAJOR SAFETY SIGNALS WERE REPORTED DURING THE
DEVELOPMENT OF
GADOPICLENOL

Source text for Eikon:  ID:nGNE21gpgk 
Further company coverage:  GRBT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))